AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Revenio Group Oyj

Major Shareholding Notification Feb 14, 2025

3236_rns_2025-02-14_f2911e68-6087-469c-aba6-93e5ca2b1eb4.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

Revenio Group Corporation: Notification of change in holdings according to Chapter 9, Section 10 of the Finnish Securities Market Act

Revenio Group Corporation | Stock Exchange Release | February 14, 2025 at 16:00:00 EET

Revenio Group Corporation has received the following notification pursuant to Chapter 9, section 5 of the Securities Markets Act ("SMA"), according to which William Demant Invest A/S voting rights in Revenio Group exceeded above 20 percent on February 13, 2025.

Total position of William Demant Invest A/S according to the notification:

% of
shares
and
voting
rights
% of shares and
voting rights
through financial
instruments
Total of
both in %
Total
number of
shares and
voting
rights of
issuer
Resulting situation on the
date on which threshold
was crossed or reached
20.02742% 20.02742% 26,681,116
Position of previous
notification (if applicable)
15.10% 15.10%

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights

Class/type of
shares,
ISIN code
Number of shares and voting
rights
% of shares and voting rights
Direct
(SMA 9:5)
Indirect (SMA 9:
6 and 9:7)
Direct
(SMA 9:5)
Indirect (SMA 9:
6 and 9:7)
FI0009010912 5,343,539 - 20.02742% -
SUBTOTAL A 5,343,539 20.02742%

For further information, please contact

CFO Robin Pulkkinen, tel. +358 50 505 9932 [email protected]

Distribution

Nasdaq Helsinki Ltd Financial Supervisory Authority (FIN-FSA) Main media www.reveniogroup.fi/en

Revenio Group in brief

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2024, the Group's net sales totaled EUR 103.5 million, with an operating profit of EUR 25.0 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

Revenio Group Corporation: Notification of change in holdings according to Chapter 9, Section 10 of the Finnish Securities Market Act

Talk to a Data Expert

Have a question? We'll get back to you promptly.